What are the recommended melatonin dosages for children aged 3 to 18 years?

Melatonin Dosing for Children

For children aged 3-18 years with sleep-onset insomnia, start with 1 mg of fast-release melatonin given 30-60 minutes before bedtime, and titrate by 1 mg every 2 weeks if needed, with a practical ceiling of 4 mg for younger children and up to 6 mg for older children. 1

Initial Dosing Strategy

• Begin with 1 mg of fast-release melatonin administered 30-60 minutes before the desired bedtime for children ≥2.6 years old who have sleep-onset insomnia 1, 2
• This low starting dose balances safety with efficacy across the pediatric age range 1
• The timing window can extend up to 3 hours before bedtime in some protocols, though 30-60 minutes is standard 1
• Recent meta-analysis data suggest that administering melatonin 3 hours before bedtime may optimize efficacy, particularly for neuropsychiatric populations 3

Dose Escalation Protocol

• Maintain the initial 1 mg dose for at least 2 weeks before considering any adjustment, allowing sufficient time to assess efficacy and tolerability 1
• If inadequate response after 2 weeks, increase by 1 mg increments every 2 weeks 1
• Maximum recommended dose is 4 mg for young children (preschool age) to limit adverse effects 1
• For older children and adolescents (6-18 years), doses up to 6 mg have been studied, though optimal efficacy occurs between 2-4 mg/day 1, 3
• Weight-based dosing of 0.05-0.15 mg/kg has been recommended by the American Academy of Sleep Medicine for children 6-12 years with delayed sleep-wake phase disorder 1

Age-Specific Considerations

Preschool Children (2.6-5 years)

• Start with 1 mg and cap at 4 mg maximum 1
• Children younger than 2 years may benefit from a 2-week acclimation phase, though use requires careful clinical judgment 1

School-Age Children (6-12 years)

• Start with 1 mg; can titrate to 4-6 mg based on response 1
• Weight-based dosing of 0.15 mg/kg (average ~4.4 mg) is optimal per AASM guidelines 1

Adolescents (13-18 years)

• Follow same titration protocol starting at 1 mg 1
• Can use higher end of dosing range (up to 6 mg) if needed 1

Special Populations

Children with Autism Spectrum Disorder

• Use same starting dose of 1 mg and titrate as needed 1
• Studies demonstrate reduction in sleep latency from approximately 43 minutes to 22 minutes with improvements in total sleep duration 1

Children with ADHD

• Weight-based dosing has been studied: 3 mg for <40 kg or 5 mg for ≥40 kg 1
• Doses of 3-6 mg administered within a few hours of bedtime have shown efficacy in children aged 6-14 years 4
• Do not extrapolate these higher doses to younger children without careful consideration 1

Children with Neuropsychiatric Conditions

• Optimal dose range remains 2-4 mg/day 3
• Longer treatment durations are associated with increased sleep efficiency and total sleep time 3

Critical Safety Warnings

• Melatonin should NOT be used concurrently with psychotropic medications unless a thorough risk-benefit assessment is performed, as such children were excluded from most efficacy studies 1
• Long-term safety data are limited in pediatric populations, particularly in young children 1, 5
• Caregivers should provide documented informed consent acknowledging the uncertain long-term safety profile 1
• Pediatric studies have not reported serious adverse reactions, but the overall benefit-to-harm assessment remains uncertain due to lack of rigorous long-term data 1

Common Adverse Effects

• Morning sleepiness occurs in approximately 60% of children who experience any adverse effect 1
• Loose stools are rare, reported in roughly 1% of cases 1
• Adverse events are generally transient and mild across all studies 4
• Napping after administration is common (47-67% of children) and may actually predict greater headache benefit in some contexts 6

Treatment Duration and Monitoring

• Most pediatricians prescribe melatonin for 1 month (37.9%) or 2-3 months (30.2%) 7
• Longer treatment durations are associated with better outcomes for sleep efficiency and total sleep time 3
• Regular monitoring by pediatricians is essential to evaluate efficacy and adverse effects 2

Clinical Pitfalls to Avoid

• Do not skip behavioral interventions first: Sleep hygiene and behavioral therapy must be the first-line approach before considering melatonin 2
• Do not use in typically developing children without first optimizing non-pharmacologic measures 2, 5
• Avoid concurrent use with other sleep medications without specialist consultation 8
• Do not assume efficacy data from children with neurologic conditions applies to typically developing children, as efficacy data for the latter population are absent 5
• Be aware that melatonin is now the leading cause of unsupervised medication exposure and overdose in emergency departments for young children aged 0-6 years 5